ReFocus Phase I/II Trial of RLY-4008 in Patients With FGFR Inhibitor–Naive Cholangiocarcinoma With FGFR2 Alteration

September 9-13, 2022; Paris, France
RLY-4008, a selective FGFR2 inhibitor, showed promising efficacy and safety in patients with FGFR inhibitor–naive cholangiocarcinoma with FGFR2 fusion or rearrangement in the phase I/II ReFocus trial.
Format: Microsoft PowerPoint (.ppt)
File Size: 203 KB
Released: September 22, 2022

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Bristol-Myers Squibb
Exelixis, Inc.
Gilead Sciences, Inc.
Merck Sharp & Dohme Corp.

Related Content

Expert analysis module on key data from ESMO World GI 2022 in gastrointestinal cancers, from Clinical Care Options (CCO)

Joleen Hubbard, MD Rachna Shroff, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: October 4, 2022 Expired: October 3, 2023

Primary results from phase III LEAP-002 study of lenvatinib with or without pembrolizumab as first-line treatment for patients with advanced hepatocellular carcinoma, presented at ESMO 2022 and reported by Clinical Care Options (CCO)

Released: September 19, 2022

From Clinical Care Options (CCO), download slides reviewing contemporary systemic therapy for HCC and BTC

James M. Cleary, MD, PhD Mark Yarchoan, MD Released: September 19, 2022

Experts highlight key studies being reported at the upcoming 2022 ESMO Congress in this commentary from Clinical Care Options (CCO)

Nicoletta Colombo, MD Robert Motzer, MD David Planchard, MD, PhD Elizabeth R. Plimack, MD, MS Rachna Shroff, MD Sara Tolaney, MD, MPH Released: September 8, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings